Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NOW you got it right! Sabby is the man behind the curtain in this whole deal. Everyone else is gone. The interim ceo runs a web tech business and most of the directors are on a part time basis. Sabby is pulling all strings and you can bet he is going to walk away with mega mega bucks. He owns 40%. Once the as is maxed he'll own 60 mil. He'll decide at what pps he wants to cash out.
Obviously the management of both Genspera and Inspyr underestimated the time needed. After the completion of mipsagargin PH II there was never a feasible supply chain of thapsagargin even if they had the opportunity to start PH III. That problem still remains today. That fact was the leading cause of the total shut down in 2018. Hard to license or partner your drug into PH III if you can't get the material that makes up your drug!
It will be 4 yrs in june and still no issued patent and this is just for a procedure. No wonder it takes forever and a fortune to get drugs to the people that could benefit from them.
NSPX has licensed a portion of the drug IP that they received from the L&C merger to Ridgeway Therapeutics. Since Ridgeway is a private co. very little is known about what the company is working on, their funding or how their work with the adenosine based drugs is progressing. It's very possible Ridgeway may be re-purposing the drugs to fight COVID-19. What is know is that Colin Hislop Ridgeway CEO has extensive experience in new drug applications and has work with both NSPX ex ceo Chris Lowe and Gilead! Ridgeway may be the wild card in getting the association with NSPX to the forefront of the covid-19 and establishing NSPX's adenosine drug validity for treatment.
Are the patents active or are the applications for the patents still active? For some reason it takes forever to get these patents actually in hand. They have been talking about these patents for 5 yrs.. it would be nice to see something from NSPX or Python confirming the patents are actually in hand!
Billions in the coronavirus aid package for the FDA and NIH to search, investigate and fast track viable drugs for the vaccine and/or treatment of COVid-19. This process has just started and is on square one of where NSPX can go. Trade the dips if you think it's doing you good but the ones who add and hold may be the ones who benefit. It may be a little bumpy but the amount of money that is going to be thrown not only in the USA but all over the world at this pandemic will be astronomical!
GILEAD'S remdesivir drug that is got the FDA approval for treatment of covid-19 is a adenosine analog based drug! NSPX owns a patent on a A2B antagonist that is also an adenosine base drug that NSPX says is a treatment for asthma and other lung ailments. COVID-19 attaches the lung. A license or partner or sale of the NSPX patent to another pharma may come soon!
Strong close after a lax luster session.. could have caved and hit the exit button but did not and closed green. I'll take up 5.4% with good volume any day!
I guess something from NSPX management other than tweets and retweets is too much to ask. Lots of interest in where this is going and any news would set this off like a firecracker!
Big Pharma Gilead probably put pressure on them to pull it down. Didn't like the competition. Big Pharma didn't get large by being the best boy scouts!
Don't try to out think this move..it'simple lay back and let it run! It will tell you where its going!
I'll take up 17% on heavy volume! What me worry!
Flippers can't stand prosperity..constantly pick over pennies when there are dollars out there! It will be this way all the way to $1.00
At this point all the DD is known ...the tape tells all!! NSPX is on a roll.. follow the money that's coming into this ticker!
Only following SEC guidelines that's good.. have a few extra days to file. no biggie. Still current and following rules. Flippers can't stand prosperity so late action is typical! Let them chase tomorrow! Great pattern developing Gap to higher in early trading then let weak hands and flippers work out their strategies. Nothing wrong with taking some profit.. that's what we are here for!
Mipsagargin is proven to be a viable tumor killer. The development has been hampered by supply issues with tapsigargin. The amount of drug needed to formulate a large scale PH III trial is presently not available. Python has patent pending to eliminate this problem and once that is issued I believe PH III will commence with a partner. It's all in the works!
8.5 million in debts is less than peanuts for a clinical stage co. One license or partnership will blow this away 10 fold. Certain factors are in the works that don't include a full blow operational company. NSPX holding the patents to valuable assets..right time and right deal IMO is now in the works. Next 30-90 days NSPX will be HUGE! Its a different world don't rely
on outdated and stale thinking! Prepare yourself for anything!
Thapisgargin strong enough to take down a camel should have no problem with a cancer tumor!
We are all wrong most of the time..but the times we are right make living good!
Mipsagargin A.K.A the "CANCER GRENADE"
Flyer has always been a balancing voice on this board. He keeps his posts to the point and relays the facts of this ticker as he sees appropriate. I don't agree with his outlook on the stock but I truly can't say I'm right and he's wrong!
I believe that most all of the DD that has been posted is correct and can be verified as true. NSPX has a strong IP portfolio and the patents on both the drug platforms are real. The PPS projections that have been put out there may or may not come to pass, but as a long time investor in the stock my PPS target has always been $1.00 but with the circumstances that have recently developed that may be low. GLTA
You are correct. At the present time there are no PH III studies or trials reported going on as reported by nspx. However, other institutions and or research entities have in the past reported that investigations into NSPX drug platforms have promoted their interest.
A few years back Dr Dionne (genspera ceo) stated the the pro drug Mipsagargin was 10X stronger than conventional chemo and had little and/or tolerable side effects. This was because the pro drug platform targeted only cancer cells and did not effect healthy cells (targeted therapy). The PH I and Ph II results basically substantiated his remarks.
GILEADS remdesivir is a prodrug with the active ingredient is an adenosine analog that may treat lung disease. Nspx owns patent on an adenosine antagonist they also may be used to treat asthma and other lung disorders. Covid-19 eventually kills by attacking the lungs!
I understand your concern..I have lived thru both R/S 2016 and 2019. I have been a basher of Chris Lowe ex ceo (FLG Partners) for his orchestrating both R/S and also the company shut down in march 2018. He is getting some redemption from me for his deal with L&C (which at the time I thought crazy). However not like you I always believed in the drug platforms and their ultimate success and although with some skepticism keep investing. Whether the investment turns out positive or not the 10yrs I have kept up with GNSZ/NSPX have been interesting!
Goodmooring.. whats your take on recent developments. Also, any update on the thapisgargin patent for python
CRAZY TIMES = CRAZY THINGS HAPPEN..anything is possible with nspx
flaflyersfan.. what happened to our nice quite nspx board! Who are all these new posters who don't know much about NSPX?
Great day..got to expect some flipping with this big move. Float about locked and MM need to entice selling by raising pps. Great setup..with ANY news this is a rocket ship!
It would seem there are powerful forces (institutional investor) behind this ticker that is in the process of a major blow up of this stock. At this point no telling what the upper limit is in the near term!
Yes.. it may get crazy today if the buyers mean business and what to join in on this CV play!
Last trade was at 4:00:34 70000 @ .0059!
#1 on the breakout board after a couple wild days!
Gilead's Remdesivir under investigation for covid-19 is an ADENOSINE based drug and some what similar to the ADENOSINE drugs that NSPX got from the L&C merger!
some heavy trade volume at the close!
That is possible.. but keep an open mind to other possibilities that exist with this ticker. Many clinical stage bios r/s to keep going until the break comes that they need.
Latest action reveals that the countdown for this launch is on the way. Many items fitting together that point the way to major happenings in this ticker! Could be soon or down the road away but no doubt its happening!
NSPX has consistently noted in their filings that their intention was to expand the drug platform obtained from L&C acquisition by means of licensing or partnering to get to a FDA new drug application in the works. Whether this process is currently ongoing is not known.. however, it is a know fact adenosine receptors are a successful treatment for many ailments including lung disorders! Used for COPD!
NSPX holds patent no. 9593118 from L&C which deals with Adenosine A2B inhibitors that may or could eventually assist in the treatment of lung associated ailments which cov-19 is one.